Stem cells containing protective genes may provide permanent control of human immunodeficiency virus (HIV) in infected individuals, according to research presented at the American Society of Gene Therapy 12th Annual Meeting, May 30.
In a landmark study, researchers demonstrated that a hematopoietic stem cell therapy could safely and effectively provide long-lasting control of HIV.
“This study was the first phase II randomized, controlled, double-blind study for cell-delivered HIV gene therapy and the first controlled HIV gene therapy study to show positive impact on viral load and CD4 count,” said Geoff Symonds, PhD, senior research director at Calimmune, Inc. “This study is a major advance in the field and it paves the way for future treatment with this new therapeutic paradigm.”
Remarkable.
No comments:
Post a Comment